Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In two placebo-controlled phase 3 trials, secukinumab, an anti–interleukin-17A monoclonal antibody, was effective in patients with ankylosing spondylitis. Adverse events associated with secukinumab included infections and neutropenia.
Ankylosing spondylitis is a chronic, immune-mediated disease that is characterized by inflammation and new bone...
Alternative Titles
Full title
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2119955049
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2119955049
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1505066
